ISR


IsoRay, Inc. (ISR) Stock Climbs On Lung Cancer Data

­ IsoRay, Inc. (NYSE MKT:ISR) IsoRay is a clinical stage biopharmaceutical company with a strong focus on treatment of cancer who’s stock is …

Company Update (NYSE MKT:ISR): Isoray, Inc.’s Cesium-131 Lung Cancer Treatment Reports 96% Success in Local Control and 100% Survival at 5 Years in High Risk Patients

IsoRay, Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced the on-line publication of the …

Company Update (NYSE MKT:ISR): Isoray, Inc. Reports Third Quarter Results

IsoRay, Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, …

Company Update (NYSE MKT:ISR): IsoRay, Inc.’s Cesium-131 Cancer Treatment Takes Center Stage at Weill Cornell’s International Symposium “Advances in Brachytherapy”

IsoRay, Inc. (NYSE MKT:ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, announced that a number of industry leaders …

Company Update (NYSE MKT:ISR): Thomas Jefferson University Launches Head and Neck Cancer Study Utilizing Cesium-131 Where Current Treatments Have Failed

IsoRay, Inc. (NYSE MKT:ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, announced the start of a new study …

Company Update (NYSE MKT:ISR): IsoRay, Inc. Cancer Fighting Isotope Cesium-131 Will Be Featured In Four Oral Presentations At The ABS Convention

IsoRay, Inc.(NYSEMKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced it will host a booth at the …

Maxim Weighs In On IsoRay Following Quarterly Results

Maxim Group analyst Jason Kolbert came out today with an update on IsoRay, Inc. (NYSE MKT:ISR), after the company released it’s fiscal second-quarter results this morning.

Maxim Comments On IsoRay Following Peer Reviewed Publication

Maxim’s healthcare analyst Jason Kolbert weighed in today with his thoughts on IsoRay Inc (NYSE:ISR), as the company announced that researchers at the University of Pittsburgh School …

ISR: UPMC Study Reports Isoray’s Cesium-131 Prostate Treatment Provides Strong Cancer Control with Lower Side Effects.

Cesium-131 Seed Brachytherapy Offers Extremely High Efficacy Compared to Other Isotopes or Treatment Modalities Used in Treating Prostate Cancer, with the Advantage of …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts